Slingshot Insights | Ptchf Overview

PTCHF Overview

Upcoming Projects (PTCHF)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (PTCHF)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (PTCHF)

Akili Labs (PTCHF) Expects to Complete STARS-ADHD Trial in March 2017 Evaluating Software Treatment EVO in Actively Reducing the Severity of ADHD in Children
Tickers: PTCHF, Akili Interactive Labs
Occurred on: May 16, 2018
Gelesis (PTCHF) Expects Readout of Pivotal Trial GLOW in H1 2017 Evaluating Gelesis100 in Weight Loss in Overweight and Obese Subjects With and Without Type 2 Diabetes
Tickers: PTCHF, Gelesis
Occurred on: Sep 25, 2017
Gelesis (PTCHF) Expects Data Readout in First Half of 2017 of 3 Month Proof-of-Concept Trial Evaluating Gelesis200 in Glycemic Control and Weight Loss in Prediabetic & Type 2 Diabetic Patients
Tickers: PTCHF, Gelesis
Occurred on: Oct 31, 2016
Tal Medical (PTCHF) Completes Phase 2 Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Tickers: PTCHF, Tal Medical
Occurred on: Oct 11, 2016
Tal Medical (PTCHF) Announces Results from Proof-of-Concept Study RAPID Evaluating Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
Tickers: PTCHF, Tal Medical
Occurred on: Jun 01, 2016
Akili Labs (PTCHF) Begins Enrollment for STARS-ADHD Trial Evaluating Software Treatment EVO in Actively Reducing the Severity of Attention Deficit Hyperactive Disorder (ADHD) in Children
Tickers: PTCHF, Akili Interactive Labs
Occurred on: May 06, 2016
Gelesis (PTCHF) Announces Safety Data from First-In-Human Study Evaluating Gelesis200 in Weight Loss and Improved Glycemic Control in Patients with Type 2 Diabetes
Tickers: PTCHF, Gelesis
Occurred on: May 03, 2016
Gelesis (PTCHF) Enrolls First Patient in Pivotal Trial GLOW Evaluating Gelesis100 in Weight Loss in Overweight and Obese Adults, Including Those with Prediabetes and Type 2 Diabetes
Tickers: PTCHF, Gelesis
Occurred on: Apr 26, 2016
Tal Medical (PTCHF) Announces Enrollment of First Patient in Phase 2 Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Tickers: PTCHF, Tal Medical
Occurred on: Sep 09, 2015
Gelesis (PTCHF) Presents Data on FLOW Proof-of-Concept Study Evaluating Gelesis100 in Carbohydrate Intake in Overweight and Obese Subjects with High Fasting Glucose at European Congress on Obesity 2015
Tickers: PTCHF, Gelesis
Occurred on: May 09, 2015
Gelesis (PTCHF) Presents Data from FLOW Proof-of-Concept Study Evaluating Gelesis100 in Glycemic Control in Non-Diabetic Overweight and Obese Subjects and Prediabetic Subjects at The Obesity Society 2014 Annual Meeting
Tickers: PTCHF, Gelesis
Occurred on: Nov 07, 2014
Gelesis (PTCHF) Presents Data from FLOW Proof-of-Concept Study Evaluating Gelesis100 in Weight Loss in Overweight and Obese Subjects at Endocrine Society Annual Meeting 2014
Tickers: PTCHF, Gelesis
Occurred on: Jun 24, 2014

Strategic Initiatives (PTCHF)

Novartis (NVS) Out-Licenses Two mTORC1 Inhibitors to PureTech (PTCHF)
Tickers: NVS, PTCHF
Announcement Date: Mar 24, 2017
Vendanta Biosciences (PTCHF) Announces Collaboration to Develop Microbiome-Derived Immunotherapies for Cancer with the Langone Medical Center of NYU
Tickers: PTCHF, Vendanta Biosciences
Announcement Date: Aug 11, 2016
Vendanta Biosciences (PTCHF) Announces $50MM Equity Raise to Advance Microbiome Therapeutics
Tickers: PTCHF, Vendanta Biosciences
Announcement Date: Jun 06, 2016
Puretech (PTCHF) Announces Launch of Alivio Therapeutics in Effort to Develop Novel Technology for Inflammatory Diseases
Tickers: PTCHF, Alivio Therapeutics
Announcement Date: May 10, 2016
Puretech (PTCHF) Announces Launch of Vor Biopharma in Effort to Expand Applicability of CAR T-Cell Immunotherapies in Immuno-Oncology
Tickers: PTCHF, Vor Biopharma
Announcement Date: May 09, 2016
Commense (PTCHF) Obtains Exclusive Worldwide License to Prevent and Treat Disease Through Microbiome-Based Interventions in Early Childhood and Names Founding Scientists and Advisors
Tickers: PTCHF, Commense Health
Announcement Date: Mar 31, 2016
Vendanta Biosciences (PTCHF) Inks License Agreement with RIKEN, the University of Tokyo, and Azabu University for New Immune Boosting Microbiome Technology
Tickers: PTCHF, Vendanta Biosciences, RIKEN
Announcement Date: Mar 30, 2016